drugset / Trial / NCT00394537

Labetalol to Prevent Hypertension and Tachycardia During Fiberoptic Bronchoscopy

NCT00394537

Phase 4 Completed 72 enrolled Rabin Medical Center
RandomizedParallel-groupDouble-blindTreatment

Summary

Passing a bronchoscope through the airways frequently causes a stress response even though patients are sedated. This stress response is usually an increase in pulse and blood pressure, which may have undesirable effects on the heart and circulation. We plan to give patients labetalol (a beta blocker which reduces pulse and blood pressure) in addition to normal sedation, to patients undergoing bronchoscopy in our department.

Timeline

Start
Primary completion
Completion
2007-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Labetalol Small molecule 10 mg Intravenous

Indications

No indication recorded.